Last Updated : April 23, 2024
Details
Generic Name:
elranatamab
Project Status:
Active
Therapeutic Area:
Relapsed or refractory multiple myeloma
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Elrexfio
Project Line:
Reimbursement Review
Project Number:
PC0315-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 05, 2023 |
|---|---|
| Call for patient/clinician input closed | October 30, 2023 |
| Clarification: - Patient input submission received from Myeloma Canada | |
| Submission received | November 09, 2023 |
| Submission accepted | November 24, 2023 |
| Review initiated | November 27, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | February 23, 2024 |
| Deadline for sponsors comments | March 05, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | March 28, 2024 |
| Expert committee meeting (initial) | April 10, 2024 |
| Draft recommendation issued to sponsor | April 23, 2024 |
| Draft recommendation posted for stakeholder feedback | May 02, 2024 |
| End of feedback period | May 16, 2024 |
Last Updated : April 23, 2024